CO2019013649A2 - Oral Solid Pharmaceutical Compositions of Dabigatran Etexilate - Google Patents

Oral Solid Pharmaceutical Compositions of Dabigatran Etexilate

Info

Publication number
CO2019013649A2
CO2019013649A2 CONC2019/0013649A CO2019013649A CO2019013649A2 CO 2019013649 A2 CO2019013649 A2 CO 2019013649A2 CO 2019013649 A CO2019013649 A CO 2019013649A CO 2019013649 A2 CO2019013649 A2 CO 2019013649A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
solid pharmaceutical
oral solid
dabigatran etexilate
etexilate
Prior art date
Application number
CONC2019/0013649A
Other languages
Spanish (es)
Inventor
Ali Türkyilmaz
Arzu Palantöken
Ezel Uraz
Yildiz Gülkok
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64559741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019013649(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2018/050221 external-priority patent/WO2019004980A2/en
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of CO2019013649A2 publication Critical patent/CO2019013649A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas sólidas orales que comprenden dabigatrán etexilato en forma de la base libre o en forma de sales, polimorfos, solvatos, hidratos o ésteres farmacéuticamente aceptables del mismo.The present invention relates to oral solid pharmaceutical compositions comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.

CONC2019/0013649A 2017-05-10 2019-12-03 Oral Solid Pharmaceutical Compositions of Dabigatran Etexilate CO2019013649A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2017/06848A TR201706848A2 (en) 2017-05-10 2017-05-10 SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE
TR2018/06309A TR201806309A2 (en) 2017-05-10 2018-05-04 Solid oral pharmaceutical compositions of dabigatran etexilate
PCT/TR2018/050221 WO2019004980A2 (en) 2017-05-10 2018-05-10 Solid oral pharmaceutical compositions of dabigatran etexilate

Publications (1)

Publication Number Publication Date
CO2019013649A2 true CO2019013649A2 (en) 2020-05-15

Family

ID=64559741

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013649A CO2019013649A2 (en) 2017-05-10 2019-12-03 Oral Solid Pharmaceutical Compositions of Dabigatran Etexilate

Country Status (8)

Country Link
EP (2) EP3621599A2 (en)
AU (1) AU2018293361B2 (en)
BR (1) BR112019023781A2 (en)
CO (1) CO2019013649A2 (en)
EA (1) EA201992644A1 (en)
NZ (1) NZ759901A (en)
TR (2) TR201706848A2 (en)
WO (1) WO2019004979A2 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
EP3858337A3 (en) * 2012-02-21 2021-09-29 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN104784147B (en) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 A kind of dabigatran etexilate methanesulfonate pharmaceutical capsules composition and preparation method thereof
IN2014MU01042A (en) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
EP2929884A1 (en) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN104095830A (en) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 Preparation method for mesylate dabigatran capsule
CN105560206A (en) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 Preparation of Pradaxa capsule
IN2015CH01145A (en) * 2015-03-09 2016-09-16
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor

Also Published As

Publication number Publication date
EA201992644A1 (en) 2020-04-07
WO2019004979A2 (en) 2019-01-03
TR201806309A2 (en) 2018-11-21
AU2018293361A1 (en) 2020-01-02
EP3634388A2 (en) 2020-04-15
BR112019023781A2 (en) 2020-06-02
NZ759901A (en) 2021-12-24
WO2019004979A3 (en) 2019-04-11
AU2018293361B2 (en) 2021-09-16
TR201706848A2 (en) 2018-11-21
EP3621599A2 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
MX2020004932A (en) Compounds useful for inhibiting cdk7.
CY1124007T1 (en) Tofacitinib Sustained-Release Oral Dosage Forms
UY35933A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AZD9291
CR20160538A (en) COMBINATION
PH12016500895B1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
DK3634468T3 (en) SOLID COMPOSITION FOR ORAL ADMINISTRATION
TR201906325T4 (en) Tetrazolone substituted dihydropyridinone MGAT2 inhibitors.
MX2017013073A (en) Ghrelin o-acyl transferase inhibitors.
MA44720A (en) ORAL DISINTEGRATION TABLETS
IN2014MN02245A (en)
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
EA202092829A1 (en) CONTROLLED RELEASE TOPACITINIB COMPOSITIONS
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
CY1123408T1 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
WO2019004980A3 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
DK3773511T3 (en) ORAL TABLET FOR INDUCED SALIVA PRODUCTION
CO2019013649A2 (en) Oral Solid Pharmaceutical Compositions of Dabigatran Etexilate
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
TR201714882A2 (en) Topical pharmaceutical compositions of luliconazole
AR107163A1 (en) QUINASE INHIBITORS
CO2017004382A2 (en) Pharmaceutical compositions comprising lobeglitazone for oral administration
EA201991288A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN
TR201722323A2 (en) Oral pharmaceutical compositions of dabigatran
TR201722186A2 (en) Pharmaceutical compositions of dabigatran
IN2014MU00859A (en)